OCA2 and gastroesophageal reflux disease: In particular, vonoprazan appears as the most established P-CAB due to its robust clinical trial evidence, and it is currently acknowledged by several treatment guidelines for the treatment of GERD (Jung et al., 2021; Xiao et al., 2021; Iwakiri et al., 2022) and H. pylori eradication (as a component of quadruple-, triple-, and dual-therapy regimens) (Kato et al., 2019; Malfertheiner et al., 2022; Zhou et al., 2022; Chey et al., 2024), and PUD (Kamada et al., 2021).